Authors
Latest:
Dr. Shahda on BBI-608 With Gemcitabine and Nab-Paclitaxel in Patients with mPDACSafi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study examining the cancer stem cell pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
Latest:
Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and BeyondChimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.
Latest:
Dr Lonial on the Impact of the CoMMpass Study on Personalized Medicine in Multiple MyelomaSagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.
Latest:
Dr Lonial on the Outcomes of the IKEMA Trial in Relapsed Multiple MyelomaSagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.
Latest:
Investigational Agents for Relapsed/Refractory MyelomaKeith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Latest:
Dr. Sampath on Safety of Immunotherapy Plus Radiation in Lung CancerSagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.
Latest:
Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLCSai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).
Latest:
Dr. Ou on the FDA Approval of Pembrolizumab in SCLCSai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).
Latest:
Dr. Ou on Alectinib as Treatment for NSCLCSai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.
Latest:
Dr. Ahmed on Optimizing Treatment With Axi-Cel in LBCLSairah Ahmed, MD, discusses optimizing treatment with axicabtagene ciloleucel in large B-cell lymphoma.
Latest:
Dr. Al-Batran on Future of Treatment in Gastric CancerSalah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.
Latest:
Sam Donaldson on the Need for Optimistic DoctorsFormer ABC News reporter Sam Donaldson, a melanoma survivor, describes the need for optimistic but realistic doctors.
Latest:
Finding Time: A Day in the Life of an Academic OncologistWe all have to balance competing demands on our time. But as an academic oncologist, I have to keep a foot in 2 worlds, research and clinical, while still keeping my balance.
Latest:
Dr. Chang on Efforts to Improve Quality of Life in Prostate CancerSam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.
Latest:
Immunotherapy at the Forefront of ALL Treatment, Expert SaysMajor advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.
Latest:
Dr. Roychowdhury on FGFR Mutations in Intrahepatic CholangiocarcinomaSameek Roychowdhury, MD, PhD, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma.
Latest:
Acute Myeloid Leukemia: Updates From The ASH 2022 Annual MeetingShared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.
Latest:
Dr. Desai on Evolving Treatment Approaches in LymphomasSameer Desai, MD, discusses current and emerging treatment options under evaluation in lymphomas.
Latest:
Unmet Needs and Future Directions in Care in CLLClosing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.
Latest:
Dr. Mikhail on Ongoing Trials in Multiple MyelomaSameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discussing ongoing trials for patients with multiple myeloma.
